标题
Immune Resistance in Lung Adenocarcinoma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 3, Pages 384
出版商
MDPI AG
发表日期
2021-01-21
DOI
10.3390/cancers13030384
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
- (2019) Ioannis Lilis et al. OncoImmunology
- Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
- (2019) Jair Bar et al. LUNG CANCER
- Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
- (2019) Patrícia Dias Carvalho et al. Cancers
- Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
- (2018) Dok Yoon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
- (2018) Antonia Marazioti et al. Nature Communications
- Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments
- (2018) Xufan Li et al. OncoImmunology
- Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
- (2017) Tomonari Kinoshita et al. EUROPEAN JOURNAL OF CANCER
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutant KRAS promotes malignant pleural effusion formation
- (2017) Theodora Αgalioti et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer
- (2017) Richard D. Hall et al. Cancer Control
- Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
- (2016) B. Bonavida et al. ANNALS OF ONCOLOGY
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Lung Cancer Subtypes Generate Unique Immune Responses
- (2016) Stephanie E. Busch et al. JOURNAL OF IMMUNOLOGY
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆
- (2016) Megan L. Hames et al. LUNG CANCER
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer
- (2016) Allyson G. McLoed et al. Cell Reports
- Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
- (2016) S. Zdanov et al. Cancer Immunology Research
- Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib
- (2015) Shingo Miyamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Mast cells mediate malignant pleural effusion formation
- (2015) Anastasios D. Giannou et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs
- (2015) Sharad K. Sharma et al. JOURNAL OF IMMUNOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- (2015) E. M. Tricker et al. Cancer Discovery
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
- (2015) Meghan Shea et al. Therapeutic Advances in Respiratory Disease
- Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer
- (2015) Seon Hee Chang OncoImmunology
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Cigarette Smoke-Induced Oxidative Stress Suppresses Generation of Dendritic Cell IL-12 and IL-23 through ERK-Dependent Pathways
- (2014) P. R. Kroening et al. JOURNAL OF IMMUNOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Entering the mainstream of cancer treatment
- (2014) Steven A. Rosenberg Nature Reviews Clinical Oncology
- T helper 17 cells play a critical pathogenic role in lung cancer
- (2014) S. H. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer
- (2014) Ji-Won Kim et al. Cancer Research and Treatment
- Annual number of lung cancer deaths potentially avertable by screening in the United States
- (2013) Jiemin Ma et al. CANCER
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Lung cancer: potential targets for immunotherapy
- (2013) Eric Tartour et al. Lancet Respiratory Medicine
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
- (2012) Lauren J. Bayne et al. CANCER CELL
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Myeloid suppressor cells and immune modulation in lung cancer
- (2012) Minu K Srivastava et al. Immunotherapy
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis
- (2011) R. Zaynagetdinov et al. JOURNAL OF IMMUNOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes
- (2011) R Zaynagetdinov et al. ONCOGENE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Receptor for Advanced Glycation End-Products Signals through Ras during Tobacco Smoke–Induced Pulmonary Inflammation
- (2010) Paul R. Reynolds et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Chemokines in cancer related inflammation
- (2010) Paola Allavena et al. EXPERIMENTAL CELL RESEARCH
- Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
- (2010) Katsuhiko Shimizu et al. Journal of Thoracic Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
- (2009) M. Santisteban et al. CANCER RESEARCH
- Targeted therapies for non-small cell lung cancer
- (2009) Wolfram C.M. Dempke et al. LUNG CANCER
- A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
- (2009) Courtney A. Granville et al. PLoS One
- Inflammation in the development of lung cancer: epidemiological evidence
- (2008) Eric A Engels Expert Review of Anticancer Therapy
- Suppression of pulmonary innate host defence in smokers
- (2008) C Herr et al. THORAX
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation